Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 79

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 79
---
 compensation plans as of the December 31, 2024, refer to “Securities Authorized for Issuance under Equity Incentive Plans” on page44.

Amendments, Termination and Requisite Shareholder Approval.Our Board may amend or terminate the 2025 Plan at any time. No amendment or termination of the 2025 Plan shall be made that would materially impair the rights of a participant under any award theretofore granted unless such participant consents to such amendment or termination. If our Board amends the 2025 Plan, it does not need stockholder approval of the amendment unless required by the terms of the 2025 Plan or applicable law, regulation or rules. Unless terminated earlier, the 2025 Plan will terminate automatically 10 years after the date when our Board adopted the 2025 Plan.

Repricing of stock options or SARs and reload grants of such awards will not be permitted without shareholder approval except in connection with certain dilutive corporate transactions described above under “Changes in Capitalization.”

Material United States Federal Income Tax and Employment Tax Consequences Relating to Participation in the 2025 Plan

The following is a summary of the material U.S. federal income tax and employment tax consequences of participation in the 2025 Plan. The discussion is based on U.S. federal tax laws and regulations as in effect on the date of this proxy statement. It is set forth solely for general information, and participants should consult their tax advisors concerning specific situations. This discussion is not intended to be a complete summary or legal interpretation, and it does not address consequences other than U.S. federal income tax and employment tax consequences. Participants in the plan might be subject to state, local and/or foreign tax as a result of their participation in the 2025 Plan.

Nonqualified Stock Options

Grant and Exercise. In general, participants will not recognize income for federal income tax purposes when they are granted an NSO. Generally, participants will recognize compensation taxable as ordinary income at the time of exercise of an NSO in an amount equal to the fair market value of the shares acquired on the date of exercise, less the exercise price paid for the shares.

Tax Basis. Participants’ tax basis in the shares they receive when they exercise an NSO for purposes of determining gain or loss on a subsequent sale or disposition of such shares generally will be the amount paid for the shares plus the amount of ordinary income the participant recognizes as a result of exercising the option. Accordingly, the tax basis of the shares generally equals the fair